Mirati Therapeutics Inc (MRTX) stock is lower by -43.43% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives MRTX stock a score of 25 out of a possible 100. That rank is primarily influenced by a short-term technical score of 2. MRTX's rank also includes a long-term technical score of 15. The fundamental score for MRTX is 59. In addition to the average rating from Wall Street analysts, MRTX stock has a mean target price of $195.75. This means analysts expect the stock to climb 59.95% over the next 12 months.
MRTX has an Overall Score of 25. Find out what this means to you and get the rest of the rankings on MRTX!